Key Market Indicator:
F&G: 43
24.947,05 NASDAQ · 48.385,00 DOW · 6.796,45 S&P · 4.308,11 Gold · 60,02 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
US04016X1019
Filter zurücksetzen
© Globe Newswire
15.12.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Article
News Preview
15 December, 2025, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces Results of Extraordinary General Meeting of Shareholders
Article
News Preview
November 18, 2025 – 10:01 PM CET...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
/C O R R E C T I O N from source -- argenx Canada Inc./
Article
News Preview
In the news release, argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada, issued 05-Nov-2025 by argenx Canada Inc. over CNW, we are advised by the company that the quote in the third paragraph has been revised. The complete, corre...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
30.10.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
$1.13 billion in third quarter global product net sales ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
29.10.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
Article
News Preview
October 29, 2025, 8:00 AM PT...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Article
News Preview
October 15, 2025, 7:00 AM CEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
Article
News Preview
October 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at Upcoming Investor Conferences
Article
News Preview
August 28, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Article
News Preview
August 25, 2025, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
Article
News Preview
August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
Article
News Preview
July 24, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
Article
News Preview
...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.06.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
Article
News Preview
June 20, 2025, 7:00 PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
Article
News Preview
June 11, 2025, 12:01 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Article
News Preview
June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
$790 million in first quarter global product net sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at BofA Securities 2025 Health Care Conference
Article
News Preview
May 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
Article
News Preview
May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Article
News Preview
April 28, 2025, 07:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.04.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
Article
News Preview
April 11, 2025, 10:01 PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Article
News Preview
April 10, 2025, 11:45 PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
Article
News Preview
April 8, 2025, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Article
News Preview
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvf...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Article
News Preview
$737 million in fourth quarter and $2.2 billion in full year global product net sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at TD Cowen 45th Annual Healthcare Conference
Article
News Preview
February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Article
News Preview
February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full yea...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Highlights 2025 Strategic Priorities
Article
News Preview
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.12.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
Article
News Preview
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at Upcoming Investor Conferences
Article
News Preview
November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Article
News Preview
November 20, 2024, 7:00 AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Participate at Upcoming Investor Conferences
Article
News Preview
November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Article
News Preview
$573 million in third quarter global net product sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
Article
News Preview
October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quar...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
Article
News Preview
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
Article
News Preview
ADHERE was largest and most innovative clinical trial of CIDP patients to date...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at Upcoming Investor Conferences
Article
News Preview
August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
Article
News Preview
$478 million in second quarter global net product sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
Article
News Preview
July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 f...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Article
News Preview
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
Article
News Preview
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Article
News Preview
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
Article
News Preview
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Article
News Preview
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
Article
News Preview
$398 million in first quarter global net product sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Present at BofA Securities 2024 Health Care Conference
Article
News Preview
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14,...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
ISIN: US04016X1019
argenx SE
ARGX
LISTED
NASDAQ
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
Article
News Preview
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 f...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Technologies
GICS Technologies is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the information technology sector.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Tuesday, 16.12.2025, Calendar Week 51, 350th day of the year, 15 days remaining until EoY.